On March 15, 2023 RS Research, a clinical-stage biotechnology start-up developing smart nanomedicines for targeted chemotherapy, reported the acceptance of a poster presentation at the European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) 2023 Congress on 6-8 March in Paris – France, being known as "The Home of Phase I in Oncology" (Press release, RS Research, MAR 15, 2023, View Source [SID1234628797]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
RS Research’s platform technology allows designing targeted drug candidates for different indications, which yields into development of the company’s own portfolio consisting of 5 drug candidates, as well as an important co-development potential. The nanocarriers introduce a versatile targeting capability and are suitable for loading a single or a combination of chemotherapeutic agents, with superior pharmacokinetic profiles while the targeting enables the drugs to accumulate in the tumor ensuring an enhanced therapeutic index and thus offering reduced toxicity profile.
RS-0139 is the lead candidate in Phase I clinical trial, aiming to deliver docetaxel specifically into integrin receptor expressing tumors such as NSCLC, breast, ovarian, prostate and pancreatic as well as head & neck carcinoma. RS Research Co-Founder and CSO Prof. Dr. Rana Sanyal and Medical Director Gülşah Nomak, MD presented the candidates’ promising preclinical data at ESMO (Free ESMO Whitepaper) TAT 2023.
Poster Title: RS-0139, a novel tumor-targeted delivery of docetaxel, with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models
Date: 6 March 2023
Location: Hall Bordeaux
Poster No: 100P
Presenter: Prof. Rana Sanyal, PhD; Co-Founder & CSO, RS Research | Gülşah Nomak, MD; Medical Director, RS Research
The poster abstract will be available online at the ESMO (Free ESMO Whitepaper) TAT 2023 website.